4. Johnson & Johnson

jnj
J&J will turn in global sales of $47.4 billion in 2024, according to Evaluate. (Johnson & Johnson)

Johnson & Johnson
Headquarters: New Brunswick, New Jersey
2017 prescription sales: $34.4 billion
Projected 2017 sales: $47.7 billion.

Johnson & Johnson’s pharma business will post strong growth in the coming years, bolstered by new drugs Imbruvica, Tremfya and Stelara, Evaluate’s report finds. In all, the drugmaker will land in the No. 4 spot by global pharma sales in 2024 with $47.4 billion that year. 

Over the next several years, J&J will produce 5% pharma growth on average, outpacing many of its rivals. Tremfya, just approved last year to treat moderate-to-severe plaque psoriasis, will grow to nearly $3.4 billion in sales by 2024, Evaluate figures. Last year, the drug turned in just $42 million in sales.  

Another drug on the upswing at J&J is Erleada, approved in March to treat prostate cancer. J&J has pegged the drug as one of its blockbuster candidates.  

Last year, after a “disappointing” first quarter, as characterized by an analyst, the company rolled out its plan to launch or submit 11 blockbuster candidates, Erleada and Tremfya among them, in the coming years. 

But even with pipeline successes, the company suffered a setback last year with sirukumab. An FDA panel rejected the rheumatoid arthritis candidate in August, and in October the company decided against pursuing global approvals. Analysts had pegged the med as a potential blockbuster. 

Aside from the recent approvals and sirukumab setback, J&J has outlined late-stage candidates in depression, acute myeloid leukemia, myelofibrosis and more. In the company’s most recent quarterly earnings release, pharma sales grew 20% over the same period last year to $10.4 billion. Stelara, Zytiga, Darzalex and Imbruvica helped fuel the growth.  

Along with progress on newer meds, the company has had success defending market share for blockbuster Remicade against biosim competition. Pfizer has sued J&J for “anticompetitive” contracting to protect the drug, arguing that J&J has tied discounts to the stipulation that payers don’t use biosims. J&J lost an early effort to throw out the case. 

Another storyline to watch is J&J’s talc litigation. The company recently suffered its biggest loss to date—worth $4.7 billion—but execs said J&J is confident the result will be overturned.  

4. Johnson & Johnson